Research Frontiers GAAP EPS of -$0.01 (REFR:NASDAQ)

Research Frontiers reported a Q3 GAAP EPS of -$0.01, with fee income declining to $77K from $359K Y/Y. Net loss widened to $510K from $299K Y/Y, while operating expenses decreased to $596K from $663K Y/Y. The company had $645K in cash and no debt as of September 30, 2026.

Original reporting
Published Nov 6, 2026, 9:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$REFR
Bearish
high confidence
Mentioned
$REFR
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$REFRBearishMed
01

Why it matters

The earnings miss is likely to trigger a sell‑off in the stock, though the strong cash position may limit downside.

02

Market read

First‑time earnings disclosure for REFR with negative surprise; relevant for traders with exposure to micro‑caps.

03

What to watch

Cash balance of $645K provides liquidity cushion; no debt reduces financial risk.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Research Frontiers (NASDAQ: REFR) released its Q3 2026 earnings, showing a GAAP loss per share and a sharp decline in fee income.

Company-level read

Ticker impact

$REFRBearishHigh confidence
Context

Q3 GAAP EPS of -$0.01, net loss widened to $510K and fee income fell to $77K.

Expected impact

downward pressure as the market prices in the widened loss and lower fee income

Evidence & confidence

The company posted a loss of $510K versus $299K a year ago and fee income collapsed, indicating weaker fundamentals.

Market effects

Signals pressure on niche research‑services sector as fee income contracts.

Limited to U.S. micro‑cap investors tracking earnings.

Low; impact confined to the company and its immediate peers.

Counterpoint

If the company can quickly cut costs, the earnings miss may be a short‑term overreaction.

Key entities

  • Research Frontiers

    Micro‑cap research‑services firm listed on NASDAQ.

Related articles

$TNYZFMed

Tiny Ltd (TNYZF) (Q3 2026) Earnings Call Highlights: Record 25% EBITDA Margin, Leverage Cut

Tiny Ltd (TNYZF) reported Q3 2026 earnings with a record 25% adjusted EBITDA margin, reduced net leverage to 2.3x, and acquired Oso Cloud for $5.3M ARR. Metalab saw 25% sequential revenue growth, while organic revenue was flat. Free cash flow improved to $8.6M. Management cautioned about sustainability of Metalab's performance and noted cost-cutting benefits are largely realized.

$SAROMed

StandardAero (SARO) Q3 2026 Earnings Call Transcript

StandardAero reported Q3 2026 earnings with 30% year-over-year adjusted EPS growth, 15% adjusted EBITDA growth, and a 130 basis points adjusted EBITDA margin expansion to 14.4%. Revenue grew across commercial aerospace, business aviation, and military & helicopter sectors. The company highlighted strong demand visibility and strategic investments driving long-term growth.

$PCTYHighAI 8/10

Paylocity (PCTY) Q1 2027 Earnings Call Transcript

Paylocity (PCTY) reported Q1 2027 recurring revenue of $424.5M, up 12% YoY, and total revenue of $451.7M, up 11%. The company launched Recruiting Optimizer, an AI-driven tool that improved recruiting productivity by 35% and filled roles 25% faster. Paylocity raised fiscal 2027 guidance and repurchased 1.1M shares at $139 each. The company highlighted strong client adoption of its AI platform and received industry recognitions.

$AHRHighAI 8/10

Healthcare REIT (AHR) Q3 2026 Earnings Call Transcript

American Healthcare REIT (AHR) reported Q3 2026 earnings with same-store NOI growth of 13.8%, raising full-year NFFO per diluted share growth guidance to over 30%. The company completed $2.1B in investments and has a $1B pipeline, while maintaining a net debt to EBITDA ratio of 1.9x. AHR emphasized its strategy of organic growth, accretive investments, and balance sheet management.